Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DCL000671

Drug Information
Name4-Aminopyridine    
SynonymsUNII-BH3B64OKL9; NINDS_000572; UPCMLD-DP125:001; p-Aminopyridine [UN2671] [Poison]; AKOS000119896; Fampridine-PR; 36687_FLUKA; 504-24-5; IDI1_034032; 4-Pyridinamine; SDCCGMLS-0066228.P001; Fampridine [USAN:INN]; KBio2_000635; Spectrum2_001413; 275875_ALDRICH; Bio1_000842; VMI103; NCGC00024890-04; KBioSS_000635; Phillips 1861; EU-0100032; Dalfampridine; InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7; KBioSS_000282; p-Aminopyridine; 4-AP; Spectrum5_001501; Lopac0_000032; KBio1_000572; LS-130202; 4-Aminopyridine Sustained Release; Amaya; Avitrol; NSC 15041; UPCMLD-DP125; Avitrol 200; NCGC00024890-01; Bio1_001331; KBio3_001888; Ampyra; NSC15041; Pymadin; KBio3_000564; Pymadine; NCGC00024890-09; Fampridine; EINECS 207-987-9; Prc 1237; Spectrum4_001013; Fampridine SR; NCGC00024890-07; NCGC00024890-02; NCGC00015009-12; 4 AP; Bio2_000762; A 0152; NCGC00024890-10; IDI1_000572; CID1727; CHEBI:34385; VMI 10-3; Fampridine (USAN/INN); HMS2092F05; NCGC00015009-03; SPECTRUM1501130; DivK1c_000572; Spectrum3_000914; Neurelan; Caswell No. 038; AC1L1C3R; 4-Aminopyridine 10; 4 Aminopyridine; Bio2_000282; Ampydin; [J.Pharmacol.Exp.Ther. 275:864 (1995)]; KBioGR_001505; VMI-103; HMS1361O04; AC1Q52BM; A78403_ALDRICH; EL-970; Compound 1861; KBio2_005418; BSPBio_001562; Mi-W-3; HC150041; pyridin-4-amine; AI3-52547; .gamma.-Aminopyridine; Bio1_000353; KBio2_002850; HMS1791O04; 4 Aminopyridine Sustained Release; Neurelan (TN); SMR000058211; BRN 0105782; NCGC00024890-05; MolPort-000-146-022; D04127; CHEMBL284348; KBio2_005771; MLS000069400; Sustained Release, 4-Aminopyridine; pyridin-4-ylamine; Pimadin (free base); NCGC00024890-08; C5H6N2; 4-aminopyridine; PYRIDINE,4-AMINO; nchem.892-comp4; KBio2_003203; gamma-Aminopyridine; KBio3_000563; AC-907/25014071; 4-Pyridylamine; FT-0083754; VMI-10-3; D015761; C13728; STK298717; Amino-4 pyridine; A0414; 5-22-09-00106 (Beilstein Handbook Reference); Philips 1861; KBioGR_000282; NCGC00015009-01; BB_SC-6974; RCRA waste no. P008; HMS1989O04; VMI 103; SPBio_001486; 36687_RIEDEL; Spectrum_000155; WLN: T6NJ DZ; Tocris-0940; Fampridine-SR; Amino-4-Pyridine; 4-Pyridinamine; Fampridine; HMS501M14; HMS1921H15; Lopac-A-0152; NCGC00024890-06; NCGC00024890-03; AB1004971; p-Aminopyridine [UN2671] [Poison]; KBio2_000282; Pyridine, 4-amino-; TL8003344; EPA Pesticide Chemical Code 069201; HSDB 6037    
CompanyAcorda Therapeutics    
IndicationSpinal cord injuryPhase III completed    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
CAS NumberCAS 504-24-5
FormularC5H6N2    
PubChem Compound IDCID 1727.    
PubChem Substance IDSID 79008.    
ChEBI34385;    
ClinicalTrials.govNCT00041717;    
TargetVoltage-gated potassium channel Kv1Blocker[1]
Ref 1Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543